1. Home
  2. SPHL vs APRE Comparison

SPHL vs APRE Comparison

Compare SPHL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$2.30

Market Cap

7.1M

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

N/A

Current Price

$0.51

Market Cap

5.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPHL
APRE
Founded
2002
2006
Country
Singapore
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
5.7M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
SPHL
APRE
Price
$2.30
$0.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $3.30
AVG Volume (30 Days)
★ 2.2M
144.6K
Earning Date
09-23-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.22
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.41
52 Week High
$25.11
$1.49

Technical Indicators

Market Signals
Indicator
SPHL
APRE
Relative Strength Index (RSI) 45.78 42.04
Support Level N/A $0.41
Resistance Level $2.98 $0.81
Average True Range (ATR) 0.50 0.06
MACD -0.03 0.01
Stochastic Oscillator 0.27 52.63

Price Performance

Historical Comparison
SPHL
APRE

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: